CDI Labs Revenue and Competitors

Be Specific™ with products and services by CDI – creators of the world’s most comprehensive protein array: HuProt™. Now introducing PhIP-Seq – with the VirScan™ and HuScan™ phage display libraries. CDI Labs was founded because we believe that many future discoveries depend on a deeper understanding of individual proteins. We’ve combined our vast proteomic libraries with a deep expertise in synthetic biology to create Monomabs™: the first proteome-validated monospecific monoclonal antibodies: http://monomabs.com And Antygen™, the multi-dimensional immunoprofiling service: http://antygen.com Join us in creating the antigen-specific revolution, and help unravel some of the greatest mysteries in human health. ---------------------------- The CDI mission is to empower research and development in proteomics with proprietary technologies, making possible — today — the protein discoveries of tomorrow. CDI's HuProt™ protein microarrays have over 21,000 individual, fully-expressed proteins, spanning >81% of the human proteome. This allows for groundbreaking antibody assay development and validation, proteome-wide profiling of patients, novel and uniquely robust biomarker discovery programs. The Company's microarray-powered monoclonal antibodies (Monomabs™) and related services provide unprecedented levels of specificity. Our system of antibody production is part of the NIH Protein Capture Reagents program (PCRP), and is currently working to produce truly mono-specific antibodies to a multitude of highly relevant human transcription factors. CDI has patents in process for technologies to increase high-throughput analysis of protein-protein interactions as well as high throughput development of antibodies and identification of biomarkers through serum profiling. At CDI we believe that partnering with both companies and academic scientists is the path to mutual success. We currently have facilities in Baltimore, Maryland and in Mayaguez, Puerto Rico.